TCGA-AC-A3W5-01A-11R-A22K-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 17
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
- ALLOGRAFT_REJECTION+0.470
- COAGULATION+0.430
- IL6_JAK_STAT3_SIGNALING+0.420
- INFLAMMATORY_RESPONSE+0.420
- MYOGENESIS+0.370
- COMPLEMENT+0.360
- TNFA_SIGNALING_VIA_NFKB+0.360
- APICAL_SURFACE+0.350
Top 10 suppressed
- MYC_TARGETS_V1-0.570
- E2F_TARGETS-0.440
- MYC_TARGETS_V2-0.430
- PROTEIN_SECRETION-0.410
- G2M_CHECKPOINT-0.360
- UNFOLDED_PROTEIN_RESPONSE-0.340
- OXIDATIVE_PHOSPHORYLATION-0.310
- DNA_REPAIR-0.300
- ESTROGEN_RESPONSE_EARLY-0.290
- MTORC1_SIGNALING-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-LD-A9QF-01A-32R-A41B-07 | — | D | 0.941 |
| 2 | TCGA-A2-A0EP-01A-52R-A22U-07 | — | A | 0.926 |
| 3 | R52 | — | — | 0.926 |
| 4 | 20120155.TNBC | — | D | 0.926 |
| 5 | TCGA-A2-A4S1-01A-21R-A266-07 | — | A | 0.910 |
| 6 | SRR8613743 | — | D | 0.907 |
| 7 | SRR35579837 | — | D | 0.901 |
| 8 | SRR2689710 | — | — | 0.896 |
| 9 | MDT-AP-1125 | Med | Medulloblastoma | 0.895 |
| 10 | 7f51ff28-397d-466f-82b0-25e9c9182ea7 | — | — | 0.894 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.550 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.530 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| COAGULATION | 0.430 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.420 | Idelalisib | — uncovered |
| MYOGENESIS | 0.370 | Inavolisib | — uncovered |
| COMPLEMENT | 0.360 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.360 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.350 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.320 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.290 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.280 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.260 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |